BioPharma Resources

Drug Trial Radar · NCT04223791

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 643 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

643

Actual

Start

Feb 18, 2020

Primary completion

Aug 26, 2021

Study completion Feb 27, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jan 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of a switch to Doravirine/Islatravir (DOR/ISL) (MK-8591A) (a fixed dose combination of doravirine 100 mg and islatravir 0.75 mg) in participants living with human immunodeficiency virus-1 (HIV-1) virologically suppressed on a regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that a switch to DOR/ISL (MK-8591A) will be non-inferior to continued treatment with BIC/FTC/TAF as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48. Participants who benefit from their assigned intervention (as determined by investigator) will be able to continue treatment through a 24-week study extension.

Conditions

  • HIV Infection

Interventions

  • DOR/ISLDrug

    100 mg DOR/ 0.75 ISL FDC single tablet taken orally once daily

  • BIC/FTC/TAFDrug

    50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily

  • Placebo to BIC/FTC/TAFDrug

    Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily

  • Placebo to FDC DOR/ISLDrug

    Placebo to FDC DOR/ISL in a single tablet taken orally, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV-1 RNA) ≥50 Copies/mL at Week 48Time frame: Week 48
  2. Percentage of Participants With One or More Adverse Events (AEs) up to Week 48Time frame: Up to 48 weeks
  3. Percentage of Participants Who Discontinued Study Intervention Due to an AE up to Week 48Time frame: Up to 48 weeks

Locations

89 sites in 11 countries. Site status is shown where the registry gives one.

  • Pueblo Family Physicians ( Site 2717)

    Phoenix, Arizona

  • Pacific Oaks Medical Group ( Site 2765)

    Beverly Hills, California

  • Men's Health Foundation ( Site 2749)

    Los Angeles, California

  • Kaiser Permanente Los Angeles Medical Center ( Site 2775)

    Los Angeles, California

  • Eisenhower Medical Center ( Site 2744)

    Palm Springs, California

  • University of California, Davis, Division of ID Research ( Site 2702)

    Sacramento, California

  • Zuckerberg San Francisco General Hospital UCSF ( Site 2743)

    San Francisco, California

  • Whitman-Walker Clinic ( Site 2728)

    Washington D.C., District of Columbia

  • TheraFirst Medical Center ( Site 2742)

    Fort Lauderdale, Florida

  • Midway Immunology and Research ( Site 2759)

    Ft. Pierce, Florida

  • The Kinder Medical Group ( Site 2739)

    Miami, Florida

  • AHF South Beach ( Site 2780)

    Miami Beach, Florida

  • Orlando Immunology Center ( Site 2734)

    Orlando, Florida

  • Triple O Research Institute, P.A. ( Site 2755)

    West Palm Beach, Florida

  • Augusta University ( Site 2752)

    Augusta, Georgia

  • Infectious Disease Specialists Of Atlanta PC ( Site 2719)

    Decatur, Georgia

  • Mercer University ( Site 2738)

    Macon, Georgia

  • Chatham County Health Department ( Site 2731)

    Savannah, Georgia

  • Hennepin County Medical Center ( Site 2733)

    Minneapolis, Minnesota

  • Kansas City CARE Clinic ( Site 2718)

    Kansas City, Missouri

  • ID Care ( Site 2751)

    Hillsborough, New Jersey

  • Icahn School of Medicine at Mount Sinai ( Site 2700)

    New York, New York

  • Montefiore Einstein Center ( Site 2730)

    The Bronx, New York

  • North Texas ID Consultants, PA ( Site 2707)

    Dallas, Texas

  • The Crofoot Research Center, Inc. ( Site 2715)

    Houston, Texas

  • DCOL Center for Clinical Research ( Site 2769)

    Longview, Texas

  • Dr. Peter Shalit, MD ( Site 2770)

    Seattle, Washington

  • Multicare Health System ( Site 2713)

    Spokane, Washington

  • St Vincent's Hospital ( Site 3807)

    Darlinghurst, New South Wales, Australia

  • Taylor Square Private Clinic ( Site 3804)

    Darlinghurst, New South Wales, Australia

  • Holdsworth House Medical Practice ( Site 3800)

    Sydney, New South Wales, Australia

  • Holdsworth House Medical Practice - Brisbane ( Site 3810)

    Brisbane, Queensland, Australia

  • Royal Brisbane and Womens Hospital- Infectious Diseases Unit ( Site 3812)

    Herston, Queensland, Australia

  • The Alfred Hospital ( Site 3802)

    Melbourne, Victoria, Australia

  • Prahran Market Clinic (PMC) ( Site 3806)

    Melbourne, Victoria, Australia

  • Medical University Vienna ( Site 3402)

    Vienna, State of Vienna, Austria

  • Sozialmedizinisches Zentrum Sued - Kaiser-Franz-Josef-Spital ( Site 3400)

    Vienna, State of Vienna, Austria

  • Social Medical Center - Otto Wagner Hospital ( Site 3404)

    Vienna, State of Vienna, Austria

  • LKH Graz West ( Site 3401)

    Graz, Styria, Austria

  • Vancouver ID Research and Care Centre Society ( Site 2800)

    Vancouver, British Columbia, Canada

Showing 40 of 89 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.